Druck Icon
 

Strong Growth at Eckert & Ziegler

Berlin, February 2nd 2005 - Eckert & Ziegler AG, a manufacturer of medical technology products for the diagnosis and treatment of cancer, was able to greatly increase its earnings and sales volume in its 2004 fiscal year. According to a preliminary assessment, Group sales volume rose by about 18% to €35 million, despite the unfavorable dollar rate development over the course of the year. The annual surplus after taxes more than tripled from € 0.28 to around € 1.05 per share, although approx. € 0.45 of that resulted from a one-time deconsolidation of biotechnology activities. For the coming year, the Executive Board expects a renewed increase in sales volume in the double-digit percentage range, and an annual surplus of € 0.50 to 0.80 per share - both without taking acquisitions into account. The exact figures for fiscal 2004 are to be announced at a financial statement press conference on March 30th, when the annual report is to be presented.

The Board of Directors